Copyright
©The Author(s) 2020.
World J Gastroenterol. Sep 21, 2020; 26(35): 5223-5247
Published online Sep 21, 2020. doi: 10.3748/wjg.v26.i35.5223
Published online Sep 21, 2020. doi: 10.3748/wjg.v26.i35.5223
Table 1 Expression and prognostic value of stress granule-associated proteins in colorectal cancer
Components | Role in SG | mRNA expression in tumors (GEPIA) | Expression in CRC patients (literature) | Overall survival (GEPIA) | Overall survival (Human Protein Atlas) |
G3BP1 | Promotes SG assembly | Up | Unknown | No significant difference | Better prognosis with high expression |
G3BP2 | Promotes SG assembly | Up | Unknown | No significant difference | Better prognosis with high expression |
USP10 | Promotes SG assembly | Up (trend) | Down in 18.6% of patients[47] | No significant difference | Better prognosis with high expression |
CAPRIN1 | Promotes SG assembly | Up | Unknown | No significant difference | Better prognosis with high expression |
UBAP2L | Promotes SG assembly | No significant difference | Unknown | No significant difference | No significant difference |
TIA1 | Promotes SG assembly | Down (trend) | sTIA1 (spliced variant) is Up[171] | Poor prognosis with high expression | Better prognosis with high expression |
TIAL1 | Promotes SG assembly | Down (trend) | Unknown | Poor prognosis with high expression | No significant difference |
DDX3 | Promotes SG assembly | No significant difference | Poor prognosis with high expression[57] | No significant difference | Better prognosis with high expression |
PABP1 | Promotes SG assembly | Up | Unknown | NA | No significant difference |
FMR1 | Promotes SG assembly | No significant difference | Unknown | No significant difference | Better prognosis with high expression |
PDCD4 | Promotes SG assembly | Down (trend) | Down[172] | No significant difference | No significant difference |
ATXN2 | Promotes SG assembly | No significant difference | Unknown | No significant difference | No significant difference |
ANG | Promotes SG assembly | No significant difference | Up | No significant difference | No significant difference |
ZFP36 | Promotes SG clearance and SG-P-Bodies fusion | Down | Down[26] | Poor prognosis with low expression (P = 0.16: trend) | No significant difference |
ZFP36L1 | Promotes SG-P-Bodies fusion | Down | Unknown | No significant difference | No significant difference |
ELAVL1 | mRNA stabilization | Up (trend) | Up[26] | No significant difference | Better prognosis with high expression |
CUGBP2 | mRNA stabilisation | No significant difference | Down[173] | No significant difference | Better prognosis with high expression |
MSI-1 | Promotes SG assembly | No significant difference | Up[54] | No significant difference | No significant difference |
KHSRP | Unknown | No significant difference | Unknown | No significant difference | No significant difference |
BAG3 | Promotes SG clearance | No significant difference | Up[174] | No significant difference | Poor prognosis with high expression |
PRMT1 | Inhibition of SG formation | Up (trend) | (Poor prognosis with high expression[119] | Better prognosis with high expression (not significant: marked trend) | Better prognosis with high expression |
PRMT5 | Inhibition of SG formation | Up (trend) | Up[175] | Better prognosis with high expression (not significant: marked trend | Better prognosis with high expression |
HDAC6 | Promotes SG assembly | Down | Up[176] | Poor prognosis with high expression (not significant: marked trend | Poor prognosis with high expression |
SIRT6 | Promotes SG assembly | No significant difference | Down[113] | No significant difference | No significant difference |
EP300 | Inhibition of SG formation | No significant difference | Up[105] | No significant difference | No significant difference |
JMJD6 | Promotes SG assembly | No significant difference | Up[121] | No significant difference but marked trend for a poor prognosis with high expression | No significant difference |
CK2 | Inhibition of SG formation | Up (trend) | Up[177] | No significant difference | Poor prognosis with high expression |
PRKAA1 (AMPK) | Promotes SG assembly | No significant difference | Up[126,127] | No significant difference | Better prognosis with high expression |
MTOR | Unclear | No significant difference | mTORC1 Up[122] | No significant difference | No significant difference |
TARDBP | Promotes SG assembly | No significant difference | Unknown | No significant difference | No significant difference |
RBFOX2 | Regulation of cell cycle | Down | Up[101] | No significant difference | No significant difference |
RACK1 | Regulation of apoptosis | Up | No significant difference | No significant difference | |
ULK1 | Promotes SG disassembly | Down | Up[178] (Poor Prognosis) | No significant difference | Poor prognosis with high expression |
ULK2 | Promotes SG disassembly | Down | Down[179] | No significant difference | No significant difference |
VCP | Promotes SG disassembly | No significant difference | Up (poor prognosis with high expression)[180] | No significant difference | No significant difference |
- Citation: Legrand N, Dixon DA, Sobolewski C. Stress granules in colorectal cancer: Current knowledge and potential therapeutic applications. World J Gastroenterol 2020; 26(35): 5223-5247
- URL: https://www.wjgnet.com/1007-9327/full/v26/i35/5223.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i35.5223